Arcus Q3 net loss $92M; casdatifan shows 34% ORR, domvanalimab 36% risk reduction

Arcus Biosciences, Inc.

2024-Q3 EPS reported -$2.11 revenue$232,000,000

Net loss $92M vs $71M YoY; revenue $48M (up from $32M) on $41M license and development services.
Cash, equivalents and securities $1.1B, providing runway into mid-2027; year-end expected $950M-$985M.
Casdatifan 100mg cohort: 34% ORR (25% confirmed), 19% primary progression, median PFS not reached.
Domvanalimab+zimberelimab reduced risk of death by 36% (HR=0.64) vs zim in 1L NSCLC; median OS not reached.
Clinical collaboration with AstraZeneca to test casdatifan + volrustomig in IO-naive ccRCC.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.